Finasteride placebo

DRUG3 trials

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), GlaxoSmithKline, Polichem S.A.

Conditions

Alopecia, AndrogeneticAndrogenetic AlopeciaProstatic HyperplasiaProstatic Hypertrophy, Benign

Phase 3

Medical Therapy of Prostatic Symptoms

CompletedNCT00021814

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Prostatic Hyperplasia, Prostatic Hypertrophy, Benign

Start: 1995-12-31End: 2001-11-30Updated: 2018-09-28

Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

CompletedNCT01231607

GlaxoSmithKlineAndrogenetic Alopecia

Start: 2010-10-28End: 2012-02-28Updated: 2018-08-10

Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

CompletedNCT03004469

Polichem S.A.Alopecia, Androgenetic

Start: 2016-08-02End: 2018-03-05Updated: 2019-06-20

Related Papers

Five-Year Outcomes of Water Vapor Therapy vs Doxazosin, Finasteride, and Combination Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Cohort Data From the Medical Therapy of Prostatic Symptoms Trial.

2025-07-17